NCT04228653View on ClinicalTrials.gov

Long-Term Follow-up Safety After DDS Implantation With/Without CDNF Infusions

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

March 20, 2019

Primary Completion Date

September 20, 2022

Study Completion Date

March 20, 2023

Conditions
Parkinson DiseaseMovement DisordersNeuro-Degenerative DiseaseNervous System DiseasesBrain Diseases
Interventions
DEVICE

Renishaw Drug Delivery System

Device that allows pharmaceuticals to be delivered into the brain is to be assessed over a period of time to inform of the long term safety of the implanted device.

Trial Locations (3)

14186

Karolinksa University Hospital, Stockholm

00029

Helsinki University Hospital, Helsinki

221 85

Skåne University Hospital, Lund

Sponsors

Collaborators (1)

Herantis Pharma Plc.
All Listed Sponsors
collaborator

Herantis Pharma Plc.

INDUSTRY

lead

Renishaw

INDUSTRY

NCT04228653 - Long-Term Follow-up Safety After DDS Implantation With/Without CDNF Infusions | Biotech Hunter | Biotech Hunter